TITLE

The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review

AUTHOR(S)
Gillies, Michelle; Palmateer, Norah; Hutchinson, Sharon; Ahmed, Syed; Taylor, Avril; Goldberg, David
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10 Issue 1, p721
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Sharing drug injecting paraphernalia other than needles and syringes (N/S) has been implicated in the transmission of Hepatitis C virus (HCV) among injecting drug users (IDU). We aimed to determine whether the provision of sterile non-N/S injecting paraphernalia reduces injecting risk behaviours or HCV transmission among IDU. Methods: A systematic search of seven databases and the grey literature for articles published January 1989- February 2010 was undertaken. Thirteen studies (twelve observational and one non-randomized uncontrolled pilot intervention) were identified and appraised for study design and quality by two investigators. Results: No studies examined the association between the provision of non-N/S injecting paraphernalia and incident HCV infection. One cross-sectional study found that individuals who frequently, compared to those who infrequently, used sterile cookers and water, were less likely to report prevalent HCV infection. Another found no association between the uptake of sterile non-N/S injecting paraphernalia and self-reported sharing of this paraphernalia. The remaining observational studies used attendance at needle and syringe exchange programmes (NSP) or safer injection facilities (SIF) that provided non-N/S injecting paraphernalia as a proxy measure. Eight studies presented adjusted odds ratios, ranging from 0.3 to 0.9, suggesting a reduced likelihood of self-reported sharing of non-N/S injecting paraphernalia associated with use of NSP or SIF. There was substantial uncertainty associated with these estimates however. Three unadjusted studies reported a reduction in the prevalence of sharing of non-N/S injecting paraphernalia over time among NSP users. Only one study reported an adjusted temporal trend in the prevalence of sharing non-N/S injecting paraphernalia, finding higher rates among non-NSP users than NSP users at each time point, and a greater reduction in sharing among non-NSP than NSP users over time. Study limitations included the use of convenience samples, self-reported exposure and outcome measures, flawed classification of the exposed and unexposed groups, and inadequate adjustment for potential confounding variables. Conclusions: The evidence to demonstrate that the provision of sterile non-N/S injecting paraphernalia reduces HCV transmission or modifies injecting risk behaviours is currently limited by an insufficient volume and quality of studies. Further research is required to inform practice and policy in this area.
ACCESSION #
57221419

 

Related Articles

  • HCV reinfection, spontaneous clearance high among injection drug users.  // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p17 

    The article discusses a study on hepatitis C virus reinfection and spontaneous clearance of reinfection among injection drug users in Australia as of December 2013.

  • Hepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago, 1997-1999. Thorpe, Lorna E.; Ouellet, Lawrence J.; Levy, Jennie R.; Williams, Ian T.; Monterroso, Edgar R. // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6 

    The prevalence, risk factors, and prevention opportunities of hepatitis C virus (HCV) in-fection were studied in a large sample of 698 young adult injection drug users (IDUs) in Chicago, 18-30 years old. Participants were recruited between 1997 and 1999 by using street outreach, targeted...

  • Therapie der chronischen Hepatitis C. Schaffstein, Stella; Rampini, Silvana K.; Müllhaupt, Beat // Praxis (16618157);4/9/2014, Vol. 103 Issue 8, p423 

    No abstract available.

  • Reply. Rimland, David; Guest, Jodie L.; Marston, Barbara // Clinical Infectious Diseases;2/1/2000, Vol. 30 Issue 2, p410 

    Responds to comments on a report by C.T. Staples and colleagues, which dealt with hepatitis C virus coinfection. HIV-infection risk factor; Prevalence of both intravenous drug abuse and hepatitis C virus infection.

  • Potential HCV vaccine "highly economically attractive" in Canada.  // PharmacoEconomics & Outcomes News;2/26/2005, Issue 472, p7 

    Discusses research being done on the economic aspects of a potential hepatitis C virus (HCV) vaccine in Canada. Reference to a study by M. D. Krahn and colleagues published in the February 18, 2005 issue of "Vaccine"; Assessment of the cost effectiveness of a potential HCV vaccine; Benefits of...

  • Approach to the Patient with Chronic Hepatitis C Virus Infection. Herrine, Steven K. // Annals of Internal Medicine;5/21/2002, Vol. 136 Issue 10, p747 

    Chronic hepatitis C virus (HCV) infection is common and often asymptomatic. Antibodies against HCV are a highly sensitive marker of infection. Molecular testing for HCV is used to confirm a positive result on antibody testing and to provide prognostic information for treatment; however,...

  • Factors associated with HIV and hepatitis C infection among regular and non-regular injection drug users in Baltimore. Graham, C. M.; Severtson, S. G.; Mitchell, M. M.; Floyd, L.; Latimer, W. W. // Retrovirology;2006 Supplement 1, Vol. 3, pP21 

    The article examines the association of HIV and hepatitis C infection prevalence and the length of time of regular injection drug use in Baltimore, Maryland. Regular users of intravenous drugs were more likely to be infected with hepatitis C virus (HCV) or HIV compared to short term injectors....

  • HCV and HIV Counseling and Testing Integration in California: An Innovative Approach to Increase HIV Counseling and Testing Rates. Stopka, Thomas J.; Marshall, Clark; Bluthenthal, Ricky N.; Webb, David S.; Truax, Steven R. // Public Health Reports;May/Jun2007 Supplement, Vol. 122, p68 

    Objectives. In California, injection drug users (IDUs) comprise the second leading risk group for human immunodeficiency virus (HIV) infection and the majority of hepatitis C virus (HCV) cases. Innovative disease screening and prevention activities are needed to improve disease surveillance and...

  • Improvements in data reporting needed to prevent, treat HCV/HBV in IDUs.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p28 

    The article discusses research on the prevalence of hepatitis C virus infection among injection drug users, by Louisa Degenhardt and colleagues, published in "The Lancet."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics